Findings

What do systematic reviews say?

14 questions · 14 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 14.3%Very low 7 · 50%Low 4 · 28.6%Moderate 1 · 7.1%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Related · question page
- FAE vs placebo · Quality of life (QoL)
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 175 participants
  Low
Related · question page
- FAE vs placebo · PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis))
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 418 participants
  Low
Related · question page
- FAE vs placebo · AEs leading to treatment discontinuation
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low
Related · question page
- FAE vs MTX · PASI 90
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 0.48 [0.05, 4.98]
  1 study · 51 participants
  Very low
Related · question page
- FAE vs placebo · PASI 50
  Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
  RR 4.55 [2.8, 7.4]
  2 studies · 247 participants
  Low

FAE vs placebo

PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 418 participants
Low

FAE vs MTX

Quality of life (QoL) ‐ not measured · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FAE vs MTX

Common nuisance AEs (not leading to treatment discontinuation) · psoriasis

It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.89 [0.77, 1.03]
1 study · 54 participants
Very low

FAE vs MTX

PASI 50 · psoriasis

It is very uncertain whether FAE changes PASI 50 compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.71 [0.41, 1.22]
1 study · 51 participants
Very low

FAE vs MTX

Percentage of participants reaching PASI 75 · psoriasis

It is very uncertain whether FAE changes PASI 75 compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.8 [0.28, 2.29]
1 study · 51 participants
Very low

FAE vs MTX

PASI 90 · psoriasis

It is very uncertain whether FAE changes PASI 90 compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.48 [0.05, 4.98]
1 study · 51 participants
Very low

FAE vs placebo

Withdrawals due to adverse events · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

FAE vs placebo

QoL · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 175 participants
Low

FAE vs placebo

Common nuisance AEs (not leading to treatment discontinuation) · psoriasis

FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 4.72 [2.45, 9.08]
1 study · 99 participants
Moderate

FAE vs placebo

PASI 50 · psoriasis

FAE may leads to higher PASI 50 compared with placebo (low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 4.55 [2.8, 7.4]
2 studies · 247 participants
Low

FAE vs placebo

Percentage of participants reaching PASI 75 · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Low

FAE vs placebo

PASI 90 ‐ not measured · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FAE vs MTX

PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

FAE vs MTX

Withdrawals due to adverse events · psoriasis

It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).

1 finding from 1 review

Oral fumaric acid esters for psoriasis 2015 · Cochrane Headline outcomes only
RR 0.19 [0.02, 1.53]
1 study · 51 participants
Very low